Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Core Insights - Can-Fite BioPharma Ltd. announced the publication of a study on Namodenoson, highlighting its protective effects against toxicity compared to traditional chemotherapy [1][2][3] - The study demonstrates Namodenoson's anti-ischemic, anti-inflammatory, anti-fibrotic, and anti-toxicity effects across multiple body systems, particularly the liver, central nervous system, and cardiovascular system [2][3] - Namodenoson is currently undergoing pivotal Phase III trials for advanced liver cancer, with Orphan Drug and Fast Track designations from the FDA and EMA [4][5] Company Overview - Can-Fite BioPharma is focused on developing small molecule drugs for oncological and inflammatory diseases, targeting multi-billion-dollar markets [6] - The company’s lead drug candidate, Piclidenoson, has shown promising results in a Phase III trial for psoriasis and is expected to enter another pivotal Phase III trial [6] - Namodenoson has shown potential in treating various cancers, including hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis, and pancreatic cancer, with a strong safety profile demonstrated in over 1,600 patients [5][6]